Published in Adv Pharmacol on January 01, 2014
SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov (2015) 1.02
Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. Pharmacol Rev (2015) 0.88
Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain. Nat Commun (2016) 0.84
Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors. Int Rev Neurobiol (2014) 0.81
Preclinical Efficacy of Novel Vesicular Monoamine Transporter 2 Inhibitors as Antagonists of d-Methamphetamine Self-Administration in Rats. J Alcohol Drug Depend (2015) 0.78
Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine. Toxicol Sci (2014) 0.76
Importance of Substrate-Coupled Proton Antiport by the Vesicular Monoamine Transporter in the Actions of Amphetamines in Drosophila Brain. J Alcohol Drug Depend (2016) 0.75
Argon blocks the expression of locomotor sensitization to amphetamine through antagonism at the vesicular monoamine transporter-2 and mu-opioid receptor in the nucleus accumbens. Transl Psychiatry (2015) 0.75
Nucleus accumbens hyperpolarization-activated cyclic nucleotide-gated channels modulate methamphetamine self-administration in rats. Psychopharmacology (Berl) (2016) 0.75
A psychomotor stimulant theory of addiction. Psychol Rev (1987) 6.42
Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev (1992) 4.03
Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology (2004) 3.52
Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. J Med Chem (2005) 3.32
New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol (2007) 3.23
Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci (1995) 2.74
Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol (2006) 2.60
A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell (1992) 2.58
A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol (2002) 2.51
VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci U S A (1997) 2.34
Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med (1954) 2.24
Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J Pharmacol Exp Ther (1997) 2.14
Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci (2003) 2.14
Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol Rev (1988) 2.14
Lobeline attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther (2001) 2.08
Neural mechanisms of drug reinforcement. Ann N Y Acad Sci (1992) 2.07
Screening a large reference sample to identify very low frequency sequence variants: comparisons between two genes. Nat Genet (2001) 2.07
Mechanism of transport and storage of neurotransmitters. CRC Crit Rev Biochem (1987) 1.99
Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A (1992) 1.95
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A (1996) 1.94
Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron (1997) 1.89
Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. J Pharmacol Exp Ther (2004) 1.83
Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron (1997) 1.83
Lobelane decreases methamphetamine self-administration in rats. Eur J Pharmacol (2007) 1.82
Lobeline inhibits the neurochemical and behavioral effects of amphetamine. J Pharmacol Exp Ther (2001) 1.77
Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. J Neurochem (1998) 1.76
Differential expression of two vesicular monoamine transporters. J Neurosci (1995) 1.75
Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther (1979) 1.65
Lobeline does not serve as a reinforcer in rats. Psychopharmacology (Berl) (2002) 1.63
Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J Mol Neurosci (1994) 1.54
Lobeline: structure-affinity investigation of nicotinic acetylcholinergic receptor binding. J Med Chem (1999) 1.53
Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2. J Pharmacol Exp Ther (2009) 1.49
Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol (1976) 1.49
Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem (2000) 1.49
Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes. Neuropharmacology (2000) 1.49
Bioenergetics of secretory vesicles. Biochim Biophys Acta (1986) 1.48
The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci (1997) 1.42
Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation (1999) 1.42
Methamphetamine self-administration by humans. Psychopharmacology (Berl) (2001) 1.40
Dopamine transporters and neuronal injury. Trends Pharmacol Sci (1999) 1.39
D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. J Neurosci (1996) 1.38
Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorg Med Chem (2005) 1.38
Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol (1995) 1.36
The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J Biol Chem (1994) 1.35
Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther (2006) 1.35
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol (1996) 1.35
Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol (1995) 1.34
Localization of drug reward mechanisms by intracranial injections. Synapse (1992) 1.33
Role of monoamine transporters in mediating psychostimulant effects. AAPS J (2005) 1.30
The lateral nucleus of the amygdala mediates expression of the amphetamine-produced conditioned place preference. J Neurosci (1991) 1.28
Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet (2005) 1.24
Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med (1998) 1.24
Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium. Proc Natl Acad Sci U S A (1992) 1.23
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther (2001) 1.20
The release of catechol amines from the amine containing granules of the adrenal medulla. Acta Physiol Scand (1958) 1.20
Self-administration of optical isomers of amphetamine and methylamphetamine by rats. J Pharmacol Exp Ther (1973) 1.18
Self-injection of amphetamine directly into the brain. Psychopharmacology (Berl) (1983) 1.13
VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann N Y Acad Sci (2011) 1.12
Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther (2011) 1.10
Destruction of dopaminergic nerve terminals in nucleus accumbens: effect on d-amphetamine self-administration. Pharmacol Biochem Behav (1979) 1.09
The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology (Berl) (2011) 1.08
Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem (1995) 1.06
Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol (1998) 1.05
[3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux. Synapse (1998) 1.02
Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease. Adv Exp Med Biol (1996) 1.02
Pharmacology of lobeline, a nicotinic receptor ligand. J Pharmacol Exp Ther (1997) 1.02
Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)-cytisine and (-)-lobeline hydrochloride and a comparison with (-)-nicotine and other nicotine-like compounds. Br J Pharmacol (1989) 1.01
The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. J Pharmacol Exp Ther (2010) 1.00
Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev (2010) 0.99
Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances. Annu Rev Pharmacol Toxicol (2008) 0.99
Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem (2000) 0.98
Conditioned place preference from intra-accumbens but not intra-caudate amphetamine injections. Life Sci (1983) 0.97
Biochemical and pharmacological characterization of [3H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex. J Neurochem (1987) 0.96
Identification of residues involved in substrate recognition by a vesicular monoamine transporter. J Biol Chem (1995) 0.95
Lobeline effects on tonic and methamphetamine-induced dopamine release. Biochem Pharmacol (2007) 0.93
The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology (Berl) (2012) 0.93
Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. Biochemistry (1989) 0.92
Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. J Biol Chem (2001) 0.92
meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther (2010) 0.91
In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl Med Biol (2009) 0.89
Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2. J Biol Chem (1997) 0.89
Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2. J Pharmacol Exp Ther (2010) 0.89
Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem Pharmacol (1982) 0.89
Peptide mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter. J Biol Chem (1997) 0.89
Molecular pharmacology of the monoamine transporter of the chromaffin granule membrane. Ann N Y Acad Sci (1987) 0.88
Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacol Biochem Behav (2013) 0.86
Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts. J Biol Chem (1993) 0.84
Individual and combined effects of methamphetamine and ketamine on conditioned place preference and NR1 receptor phosphorylation in rats. Neurosignals (2008) 0.84
Dopamine and noradrenaline transport into subcellular vesicles of the striatum. Naunyn Schmiedebergs Arch Pharmacol (1973) 0.83
Heteroaromatic analogs of 1-[2-(diphenylmethoxy)ethyl]- and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors. J Med Chem (1997) 0.83
Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo. J Neurochem (2013) 0.81
GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine. J Neurochem (2013) 0.80
Phencyclidine: effect on the accumulation of 3H-dopamine in synaptic vesicles. Life Sci (1980) 0.79
Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites. Eur J Neurosci (1996) 0.79
The photoactivatable inhibitor 7-azido-8-iodoketanserin labels the N terminus of the vesicular monoamine transporter from bovine chromaffin granules. Biochemistry (1997) 0.78
Conditions required for reserpine binding to the catecholamine transporter on chromaffin granule ghosts. Eur J Pharmacol (1982) 0.76
Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse (1998) 0.75